COVID-19: Keep up to date with the latest pharmaceutical and healthcare news as the pandemic evolves

A critical juncture

Leslie Galloway looks back over 2020, outlining the challenges faced by the life sciences sector and the potential opportunities that lie ahead
Responding to the crisis

Oli Hudson explores the changes that have occurred in the NHS this year as the Long Term Plan has been rolled out at speed in response to the COVID crisis
Movers and shakers

As mega deals slow, private capital becomes the driving force behind 2020 M&A

News

View all

Boehringer Ingelheim and Enara Bio join forces to discover cancer immunotherapies

Agreement will leverage Enara's novel Dark Antigen discovery platform

15th January 2021

Verona completes enrolment in pilot study of potential COVID-19 inhaler

Ensinfentrine is a first-in-class inhaled inhibitor of the enzymes phosphodiesterase 3 and 4

15th January 2021

US breakthrough designation for ligelizumab in chronic spontaneous urticaria

In a Phase IIb trial, more patients experienced complete resolution of hives with ligelizumab compared to Xolair

15th January 2021

NICE backs GSK’s Zejula in advanced ovarian cancer

Zejula has been recommended for use in newly diagnosed ovarian cancer patients

15th January 2021

NHS England selects supermarket Asda to operate COVID-19 vaccination centre

Qualified pharmacists will administer the Pfizer/BioNTech vaccine at an in-store pharmacy

14th January 2021

Web Exclusives

View all

A threat to innovation?

Could recent legal decisions on Supplementary Protection Certificates (SPCs) prove to be a hammer blow for the pharma industry?

Progress in personalised renal dosing

Dose adjustment based on a patient's renal function is a very current example of personalising therapy. While this kind of precision medicine holds great potential, it is often overlooked, particularly in younger patients. Darcie Streetman and Rachel Eyler explore the growing knowledge and tools available for optimising renal dosing.

Addressing inequalities in access to care

Improving standards of care nationwide with edge computing

2020's legal hurdles for pharma

The year's legal decisions affecting the pharma industry

Magazine

View more from the latest edition

SMART PEOPLE INSIGHT: Dr Jan Westerink

A new, pooled analysis of data from Novo Nordisk’s Phase III trials SUSTAIN 6 and PIONEER 6 shows that semaglutide may help patients with type 2 diabetes live longer without a cardiovascular event. PharmaTimes talks to lead study investigator Dr Jan Westerink about the importance of these findings

Targeting treatment

Will COVID help accelerate a more personalised approach to medicine?

Planning for the unpredictable

What 2020 has taught the pharma industry about the necessity of transforming regulatory information management

R&D trends

Accelerating innovation and its impact on patients and sites

Being a patient in 2020

Jenny Ousbey outlines the patient experience and developments in advocacy

Movers and shakers

As mega deals slow, private capital becomes the driving force behind 2020 M&A

Responding to the crisis

Oli Hudson explores the changes that have occurred in the NHS this year as the Long Term Plan has been rolled out at speed in response to the COVID crisis